Clinical trials
Active, not recruiting Leukemia, B-Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| German CLL Study Group | 2 |
| Acerta Pharma BV | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| AstraZeneca | 1 |
| Dana-Farber Cancer Institute | 1 |
| French Innovative Leukemia Organisation | 1 |
| MacroGenics | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, B-Cell | 19 |
| Leukemia | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Leukemia, Lymphoid | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Lymphoma | 4 |
| Lymphoma, B-Cell | 4 |
Trials
Showing 26 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.